TY - JOUR
T1 - The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium
AU - Frisoni, Giovanni B.
AU - Henneman, Wouter J P
AU - Weiner, Michael W.
AU - Scheltens, Philip
AU - Vellas, Bruno
AU - Reynish, Emma
AU - Hudecova, Jaroslava
AU - Hampel, Harald
AU - Burger, Katharina
AU - Blennow, Kaj
AU - Waldemar, Gunhild
AU - Johannsen, Peter
AU - Wahlund, Lars Olof
AU - Zito, Giancarlo
AU - Rossini, Paolo M.
AU - Winblad, Bengt
AU - Barkhof, Frederik
PY - 2008/7
Y1 - 2008/7
N2 - Background: In North America, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has established a platform to track the brain changes of Alzheimer's disease. A pilot study has been carried out in Europe to test the feasibility of the adoption of the ADNI platform (pilot E-ADNI). Methods: Seven academic sites of the European Alzheimer's Disease Consortium (EADC) enrolled 19 patients with mild cognitive impairment (MCI), 22 with AD, and 18 older healthy persons by using the ADNI clinical and neuropsychological battery. ADNI compliant magnetic resonance imaging (MRI) scans, cerebrospinal fluid, and blood samples were shipped to central repositories. Medial temporal atrophy (MTA) and white matter hyperintensities (WMH) were assessed by a single rater by using visual rating scales. Results: Recruitment rate was 3.5 subjects per month per site. The cognitive, behavioral, and neuropsychological features of the European subjects were very similar to their U.S. counterparts. Three-dimensional T1-weighted MRI sequences were successfully performed on all subjects, and cerebrospinal fluid samples were obtained from 77%, 68%, and 83% of AD patients, MCI patients, and controls, respectively. Mean MTA score showed a significant increase from controls (left, right: 0.4, 0.3) to MCI patients (0.9, 0.8) to AD patients (2.3, 2.0), whereas mean WMH score did not differ among the three diagnostic groups (between 0.7 and 0.9). The distribution of both MRI markers was comparable to matched US-ADNI subjects. Conclusions: Academic EADC centers can adopt the ADNI platform to enroll MCI and AD patients and older controls with global cognitive and structural imaging features remarkably similar to those of the US-ADNI.
AB - Background: In North America, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has established a platform to track the brain changes of Alzheimer's disease. A pilot study has been carried out in Europe to test the feasibility of the adoption of the ADNI platform (pilot E-ADNI). Methods: Seven academic sites of the European Alzheimer's Disease Consortium (EADC) enrolled 19 patients with mild cognitive impairment (MCI), 22 with AD, and 18 older healthy persons by using the ADNI clinical and neuropsychological battery. ADNI compliant magnetic resonance imaging (MRI) scans, cerebrospinal fluid, and blood samples were shipped to central repositories. Medial temporal atrophy (MTA) and white matter hyperintensities (WMH) were assessed by a single rater by using visual rating scales. Results: Recruitment rate was 3.5 subjects per month per site. The cognitive, behavioral, and neuropsychological features of the European subjects were very similar to their U.S. counterparts. Three-dimensional T1-weighted MRI sequences were successfully performed on all subjects, and cerebrospinal fluid samples were obtained from 77%, 68%, and 83% of AD patients, MCI patients, and controls, respectively. Mean MTA score showed a significant increase from controls (left, right: 0.4, 0.3) to MCI patients (0.9, 0.8) to AD patients (2.3, 2.0), whereas mean WMH score did not differ among the three diagnostic groups (between 0.7 and 0.9). The distribution of both MRI markers was comparable to matched US-ADNI subjects. Conclusions: Academic EADC centers can adopt the ADNI platform to enroll MCI and AD patients and older controls with global cognitive and structural imaging features remarkably similar to those of the US-ADNI.
KW - ADNI
KW - Alzheimer's disease
KW - CSF
KW - EADC
KW - Imaging
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=45849116949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45849116949&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2008.04.009
DO - 10.1016/j.jalz.2008.04.009
M3 - Article
C2 - 18631976
AN - SCOPUS:45849116949
VL - 4
SP - 255
EP - 264
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 4
ER -